Use of the quality management system 'JACIE' and outcome after hematopoietic stem cell transplantation

Haematologica

Volumn 99, Issue 5, 2014, Pages 908-915

  Gratwohl, Alois ^a   Brand, Ronald ^b   McGrath, Eoin ^c   van Biezen, Anja ^b   Sureda, Anna ^d   Ljungman, Per ^e   Baldomero, Helen ^f   Chabannon, Christian ^g   Apperley, Jane ^h  

^a UNIVERSITY OF BASEL   (Switzerland)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c JACIE Accreditation Office   (Spain)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g INSTITUT PAOLI CALMETTES   (France)

^h HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACCREDITATION; ACUTE LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHILD; CHRONIC LEUKEMIA; FEMALE; FOLLOW UP; HAZARD RATIO; HEALTH CARE QUALITY; HEALTH CENTER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFORMATION SYSTEM; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOPROLIFERATIVE NEOPLASM; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME; OUTCOME ASSESSMENT; PATIENT CARE; QUALITY CONTROL; RECURRENT DISEASE; STANDARDS;

ACCREDITATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MORTALITY; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT CARE TEAM; QUALITY ASSURANCE, HEALTH CARE; QUALITY CONTROL; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TOTAL QUALITY MANAGEMENT;

EID: 84899704884     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.096461     Document Type: Article

References (39)

1. Buzzell RD, Gale BD, The PIMS Principles. Linking Strategy to Performance. New York: The Free Press; 1987.
2. Ryan J. Making the economic case for quality. An ASQ white paper. American Society for Quality. (cited 2013 March 14). Available from: http://rube. asq. org/pdf/economiccase/economic-case. pdf.
3. Hendricks KB, Singhal VR. Does implementing an effective TQM program actually improve operating performance? Empirical evidence from firms that have won quality awards. Manage Sci. 1997; 43 (9): 1258-74.
4. Cole RE. What really happened to Toyota? MIT Sloan Manage Rev. 2011; 52(2): 28-35.
5. Punnakitikashem P, Laosirihongthong T, Adebanjo D, McLean MW. A study of quality management practices in TQM and non-TQM firms: findings from the ASEAN automotive industry. Int J Qual Reliab Manag. 2010; 27(9): 1021-35.
6. Phan AC, Abdallah AB, Matsui Y. Quality management practices and competitive performance: Empirical evidence from Japanese manufacturing companies. Int J Prod Econ. 2011; 133(2): 518-29.
7. Talib F, Rahman Z. Impact of total quality management and service quality in the banking sector. J Telecomm Syst Manag. 2012; (2)1: 1-5.
8. Khodosevych LT. [Experience in the development and implementation of a complex quality management system for pharmaceutical production and drug supply]. Farm Zh. 1978; 6: 21-5.
9. Donabedian A. The effectiveness of quality assurance. Int J Qual Health Care. 1996; 8(4): 401-7. Erratum in: Int J Qual Health Care 1997; 9(4): 312.
10. Westgard JO, Barry PL, Tomar RH. Implementing total quality management (TQM) in health-care laboratories. Clin Lab Manage Rev. 1991; 5(5): 353-5, 358-9, 362-6 passim.
11. Stefl ME. The Toyota way to healthcare excellence: increase efficiency and improve quality with lean. Inquiry. 2009; 46(1): 109-10.
12. Rutledge J, Xu M, Simpson J. Application of the Toyota production system improves core laboratory operations. Am J Clin Pathol. 2010; 133(1): 24-31.
13. Lopez F, Di Bartolo C, Piazza T Passannanti A, Gerlach JC, Gridelli B, et al. A quality risk management model approach for cell therapy manufacturing. Risk Anal. 2010; 30(12): 1857-71.
14. Zahnd D, Leibundgut K, Zenhäusern R, Pabst T, Fontana S, Schneider R, et al. Implementation of the JACIE standards for a haematopoietic progenitor cell transplantation programme: a cost analysis. Bone Marrow Transplant. 2004; 34(10): 847-53.
15. Greenfield D, Pawsey M, Hinchcliff R, Moldovan M, Braithwaite J. The standard of healthcare accreditation standards: a review of empirical research underpinning their development and impact. BMC Health Serv Res. 2012; 12: 329.
16. Voelker R. Cancer care accreditation standards: improve quality and help patients cope. JAMA. 2011; 306(12): 1314.
17. Apperley J. Just another cost increasing exercise (JACIE)? Bone Marrow Transplant. 2004; 34(10): 835-8.
18. Hinchcliff R, Greenfield D, Moldovan M, Westbrook JI, Pawsey M, Mumford V, et al. Narrative synthesis of health service accreditation literature. BMJ Qual Saf. 2012; 21(12): 979-91.
19. McMahon LF Jr, Chopra V. Health care cost and value: the way forward. JAMA. 2012; 307(7): 671-2.
20. Shaw CD, Braithwaite J, Moldovan M, Nicklin W, Grgic I, Fortune T, et al. Profiling health-care accreditation organizations: an international survey. Int J Qual Health Care. 2013; 25(3): 222-31.
21. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006; 354(17): 1813-26.
22. Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med. 2007; 357 (15): 1472-5.
23. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010; 363(22): 2091-1.
24. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010; 303(16): 1617-24.
25. Warkentin PI; Foundation for the Accreditation of Cellular Therapy. Voluntary accreditation of cellular therapies: Foundation for the Accreditation of Cellular Therapy (FACT). Cytotherapy. 2003; 5(4): 299-305.
26. Kvalheim G, Gratwohl A, Urbano-Ispizua A; JACIE national representatives. JACIE accreditation in Europe moves ahead. Cytotherapy. 2003; 5(4): 306-8.
27. Gratwohl A, Brand R, Niederwieser D, Baldomero H, Chabannon C, Cornelissen J, et al. Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol. 2011; 29(15): 1980-6.
28. Gratwohl A. The EBMT risk score. Bone Marrow Transplant. 2012; 47(6): 749-56.
29. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998; 352 (9134): 1087-92.
30. Caunday O, Agulles O, McGrath E, Empereur F, Stoltz JF, Chabannon C. Implementation of JACIE accreditation results in the establishment of new indicators that unevenly monitor processes contributing to the delivery of hematopoietic SCT. Bone Marrow Transplant. 2013; 38(4): 604-9.
31. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003; 349(22): 2117-27.
32. Thiemann DR, Coresh J, Oetgen WJ, Powe NR. The association between hospital volume and survival after acute myocardial infarction in elderly patients. N Engl J Med. 1999; 340(21): 1640-8.
33. Biau DJ, Halm JA, Ahmadieh H, Capello WN, Jeekel J, Boutron I, et al. Provider and center effect in multicenter randomized controlled trials of surgical specialties: an analysis on patient-level data. Ann Surg. 2008; 247(5): 892-8.
34. Vinocur JM, Menk JS, Connett J, Moller JH, Kochilas LK. Surgical volume and center effects on early mortality after pediatric cardiac surgery: 25-year north american experience from a multi-institutional registry. Pediatr Cardiol. 2013; 34(5): 1226-36.
35. Frassoni F, Labopin M, Powles R, Mary JY, Arcese W, Bacigalupo A, et al. Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 2000; 355(9213): 1393-8.
36. Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, et al. Recommended screening and preventive practices for longterm survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012; 18(3): 348-71.
37. Gratwohl A. Organ donation: stricter management of organ transplants. Nature. 2012; 488(7412): 459.
38. World Health Organization. WHO guiding principles on human cell, tissue and organ transplantation. Transplantation. 2010; 90(3): 229-33.
39. Barbui T, Björkholm M, Gratwohl A. Optimizing investigator-led oncology research in Europe. Haematologica. 2012; 97 (6): 800-4.